Does the media prefer GLUE or RZLT?

In the previous week, Monte Rosa Therapeutics had 6 more articles in the media than Rezolute. MarketBeat recorded 8 mentions for Monte Rosa Therapeutics and 2 mentions for Rezolute. Rezolute's average media sentiment score of 0.31 beat Monte Rosa Therapeutics' score of 0.30 indicating that Rezolute is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monte Rosa Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rezolute 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, SLS or RZLT?

SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SELLAS Life Sciences Group N/A N/A -$26.86M -$0.23 N/A Rezolute N/A N/A -$74.41M -$0.82 N/A

Is SLS or RZLT more profitable?

SELLAS Life Sciences Group's return on equity of -47.12% beat Rezolute's return on equity. Company Net Margins Return on Equity Return on Assets SELLAS Life Sciences Group N/A -47.12% -42.63% Rezolute N/A -58.82% -54.48%

Does the media favor SLS or RZLT?

In the previous week, SELLAS Life Sciences Group had 2 more articles in the media than Rezolute. MarketBeat recorded 4 mentions for SELLAS Life Sciences Group and 2 mentions for Rezolute. SELLAS Life Sciences Group's average media sentiment score of 0.53 beat Rezolute's score of 0.31 indicating that SELLAS Life Sciences Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SELLAS Life Sciences Group 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rezolute 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CAPR or RZLT more profitable?

Rezolute's return on equity of -58.82% beat Capricor Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Capricor Therapeutics N/A -59.27% -48.65% Rezolute N/A -58.82% -54.48%

Does the media favor CAPR or RZLT?

In the previous week, Capricor Therapeutics and Capricor Therapeutics both had 2 articles in the media. Capricor Therapeutics' average media sentiment score of 0.66 beat Rezolute's score of 0.31 indicating that Capricor Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Capricor Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rezolute 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is RZLT or IMCR more profitable?

Rezolute has a net margin of 0.00% compared to Immunocore's net margin of -6.68%. Immunocore's return on equity of -7.07% beat Rezolute's return on equity. Company Net Margins Return on Equity Return on Assets Rezolute N/A -58.82% -54.48% Immunocore -6.68% -7.07% -2.55%

Does the media favor RZLT or IMCR?

In the previous week, Rezolute and Rezolute both had 2 articles in the media. Immunocore's average media sentiment score of 1.15 beat Rezolute's score of 0.31 indicating that Immunocore is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rezolute 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immunocore 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RZLT or VIR?

In the previous week, Rezolute had 1 more articles in the media than Vir Biotechnology. MarketBeat recorded 2 mentions for Rezolute and 1 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 0.67 beat Rezolute's score of 0.31 indicating that Vir Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rezolute 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vir Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Rezolute (RZLT) Competitors

$4.89 -0.26 (-5.05%)

Closing price 04:00 PM Eastern

Extended Trading

$4.89 +0.00 (+0.10%)

As of 07:45 PM Eastern

Compare

RZLT vs. GLUE, SLS, CAPR, IMCR, and VIR

Should you buy Rezolute stock or one of its competitors? MarketBeat compares Rezolute with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Rezolute include Monte Rosa Therapeutics (GLUE), SELLAS Life Sciences Group (SLS), Capricor Therapeutics (CAPR), Immunocore (IMCR), and Vir Biotechnology (VIR). These companies are all part of the "pharmaceutical products" industry.

How does Rezolute compare to Monte Rosa Therapeutics?

Monte Rosa Therapeutics (NASDAQ:GLUE) and Rezolute (NASDAQ:RZLT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends.

Monte Rosa Therapeutics presently has a consensus price target of $32.50, suggesting a potential upside of 56.93%. Rezolute has a consensus price target of $9.38, suggesting a potential upside of 91.72%. Given Rezolute's higher probable upside, analysts plainly believe Rezolute is more favorable than Monte Rosa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monte Rosa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Rezolute	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. Comparatively, 83.0% of Rezolute shares are owned by institutional investors. 6.4% of Monte Rosa Therapeutics shares are owned by insiders. Comparatively, 14.8% of Rezolute shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Rezolute has a net margin of 0.00% compared to Monte Rosa Therapeutics' net margin of -302.69%. Monte Rosa Therapeutics' return on equity of -40.99% beat Rezolute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monte Rosa Therapeutics	-302.69%	-40.99%	-25.94%
Rezolute	N/A	-58.82%	-54.48%

In the previous week, Monte Rosa Therapeutics had 6 more articles in the media than Rezolute. MarketBeat recorded 8 mentions for Monte Rosa Therapeutics and 2 mentions for Rezolute. Rezolute's average media sentiment score of 0.31 beat Monte Rosa Therapeutics' score of 0.30 indicating that Rezolute is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monte Rosa Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rezolute	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Monte Rosa Therapeutics has higher revenue and earnings than Rezolute. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monte Rosa Therapeutics	$123.67M	14.15	-$38.63M	-$1.48	N/A
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A

Monte Rosa Therapeutics has a beta of 1.6, indicating that its stock price is 60% more volatile than the broader market. Comparatively, Rezolute has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market.

Summary

Rezolute beats Monte Rosa Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Rezolute compare to SELLAS Life Sciences Group?

SELLAS Life Sciences Group (NASDAQ:SLS) and Rezolute (NASDAQ:RZLT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.

SELLAS Life Sciences Group has a beta of 2.5, indicating that its stock price is 150% more volatile than the broader market. Comparatively, Rezolute has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market.

SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.23	N/A
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A

17.4% of SELLAS Life Sciences Group shares are held by institutional investors. Comparatively, 83.0% of Rezolute shares are held by institutional investors. 1.3% of SELLAS Life Sciences Group shares are held by insiders. Comparatively, 14.8% of Rezolute shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

SELLAS Life Sciences Group's return on equity of -47.12% beat Rezolute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SELLAS Life Sciences Group	N/A	-47.12%	-42.63%
Rezolute	N/A	-58.82%	-54.48%

SELLAS Life Sciences Group presently has a consensus target price of $10.00, suggesting a potential upside of 10.25%. Rezolute has a consensus target price of $9.38, suggesting a potential upside of 91.72%. Given Rezolute's stronger consensus rating and higher possible upside, analysts clearly believe Rezolute is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Rezolute	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

In the previous week, SELLAS Life Sciences Group had 2 more articles in the media than Rezolute. MarketBeat recorded 4 mentions for SELLAS Life Sciences Group and 2 mentions for Rezolute. SELLAS Life Sciences Group's average media sentiment score of 0.53 beat Rezolute's score of 0.31 indicating that SELLAS Life Sciences Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SELLAS Life Sciences Group	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rezolute	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

SELLAS Life Sciences Group beats Rezolute on 7 of the 13 factors compared between the two stocks.

How does Rezolute compare to Capricor Therapeutics?

Capricor Therapeutics (NASDAQ:CAPR) and Rezolute (NASDAQ:RZLT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.

21.7% of Capricor Therapeutics shares are held by institutional investors. Comparatively, 83.0% of Rezolute shares are held by institutional investors. 9.2% of Capricor Therapeutics shares are held by company insiders. Comparatively, 14.8% of Rezolute shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Capricor Therapeutics has a beta of 0.39, indicating that its stock price is 61% less volatile than the broader market. Comparatively, Rezolute has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market.

Rezolute's return on equity of -58.82% beat Capricor Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capricor Therapeutics	N/A	-59.27%	-48.65%
Rezolute	N/A	-58.82%	-54.48%

In the previous week, Capricor Therapeutics and Capricor Therapeutics both had 2 articles in the media. Capricor Therapeutics' average media sentiment score of 0.66 beat Rezolute's score of 0.31 indicating that Capricor Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Capricor Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rezolute	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Rezolute has lower revenue, but higher earnings than Capricor Therapeutics. Capricor Therapeutics is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capricor Therapeutics	$22.27M	76.97	-$105.04M	-$2.32	N/A
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A

Capricor Therapeutics currently has a consensus price target of $48.36, suggesting a potential upside of 63.39%. Rezolute has a consensus price target of $9.38, suggesting a potential upside of 91.72%. Given Rezolute's higher probable upside, analysts plainly believe Rezolute is more favorable than Capricor Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capricor Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Rezolute	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Summary

Rezolute beats Capricor Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Rezolute compare to Immunocore?

Rezolute (NASDAQ:RZLT) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

Rezolute currently has a consensus target price of $9.38, indicating a potential upside of 91.72%. Immunocore has a consensus target price of $56.71, indicating a potential upside of 94.23%. Given Immunocore's higher possible upside, analysts clearly believe Immunocore is more favorable than Rezolute.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rezolute	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Immunocore	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56

Rezolute has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market. Comparatively, Immunocore has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market.

Immunocore has higher revenue and earnings than Rezolute. Immunocore is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A
Immunocore	$412.81M	3.60	-$35.51M	-$0.55	N/A

Rezolute has a net margin of 0.00% compared to Immunocore's net margin of -6.68%. Immunocore's return on equity of -7.07% beat Rezolute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rezolute	N/A	-58.82%	-54.48%
Immunocore	-6.68%	-7.07%	-2.55%

83.0% of Rezolute shares are owned by institutional investors. Comparatively, 84.5% of Immunocore shares are owned by institutional investors. 14.8% of Rezolute shares are owned by company insiders. Comparatively, 10.1% of Immunocore shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Rezolute and Rezolute both had 2 articles in the media. Immunocore's average media sentiment score of 1.15 beat Rezolute's score of 0.31 indicating that Immunocore is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rezolute	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immunocore	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Immunocore beats Rezolute on 10 of the 15 factors compared between the two stocks.

How does Rezolute compare to Vir Biotechnology?

Rezolute (NASDAQ:RZLT) and Vir Biotechnology (NASDAQ:VIR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

Rezolute has higher earnings, but lower revenue than Vir Biotechnology. Rezolute is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A
Vir Biotechnology	$64.69M	26.49	-$437.99M	-$3.13	N/A

Rezolute currently has a consensus target price of $9.38, indicating a potential upside of 91.72%. Vir Biotechnology has a consensus target price of $20.88, indicating a potential upside of 105.46%. Given Vir Biotechnology's stronger consensus rating and higher possible upside, analysts clearly believe Vir Biotechnology is more favorable than Rezolute.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rezolute	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Rezolute has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market. Comparatively, Vir Biotechnology has a beta of 1.65, indicating that its share price is 65% more volatile than the broader market.

83.0% of Rezolute shares are owned by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are owned by institutional investors. 14.8% of Rezolute shares are owned by company insiders. Comparatively, 2.9% of Vir Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Rezolute has a net margin of 0.00% compared to Vir Biotechnology's net margin of -638.88%. Vir Biotechnology's return on equity of -53.31% beat Rezolute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rezolute	N/A	-58.82%	-54.48%
Vir Biotechnology	-638.88%	-53.31%	-41.76%

In the previous week, Rezolute had 1 more articles in the media than Vir Biotechnology. MarketBeat recorded 2 mentions for Rezolute and 1 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 0.67 beat Rezolute's score of 0.31 indicating that Vir Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rezolute	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vir Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Vir Biotechnology beats Rezolute on 9 of the 16 factors compared between the two stocks.

Get Rezolute News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RZLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RZLT vs. The Competition

Export

Metric	Rezolute	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$495.90M	$3.45B	$6.45B	$12.39B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-5.96	19.75	24.92	23.98
Price / Sales	N/A	330.11	529.01	109.54
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	2.63	8.29	10.79	6.50
Net Income	-$74.41M	$23.85M	$3.56B	$336.88M
7 Day Performance	7.00%	5.21%	1.67%	-0.22%
1 Month Performance	50.46%	2.19%	0.43%	0.77%
1 Year Performance	21.34%	60.99%	32.84%	31.57%

Rezolute Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RZLT Rezolute	3.4052 of 5 stars	$4.89 -5.0%	$9.38 +91.7%	+25.3%	$495.90M	N/A	N/A	40	Analyst Upgrade
GLUE Monte Rosa Therapeutics	1.8377 of 5 stars	$18.12 -0.7%	$32.50 +79.4%	+303.2%	$1.54B	$123.67M	N/A	90	Positive News
SLS SELLAS Life Sciences Group	0.7579 of 5 stars	$7.73 -1.3%	$10.00 +29.4%	+453.9%	$1.54B	N/A	N/A	10	Options Volume
CAPR Capricor Therapeutics	2.0226 of 5 stars	$26.72 +3.6%	$48.36 +81.0%	+255.2%	$1.49B	$22.27M	N/A	101	Gap Down
IMCR Immunocore	3.3779 of 5 stars	$28.63 -1.1%	$56.71 +98.1%	-6.3%	$1.47B	$400.02M	N/A	320	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RZLT) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rezolute (RZLT) Competitors

RZLT vs. GLUE, SLS, CAPR, IMCR, and VIR

How does Rezolute compare to Monte Rosa Therapeutics?

Summary

How does Rezolute compare to SELLAS Life Sciences Group?

Summary

How does Rezolute compare to Capricor Therapeutics?

Summary

How does Rezolute compare to Immunocore?

Summary

How does Rezolute compare to Vir Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RZLT vs. The Competition

Rezolute Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rezolute (RZLT) Competitors

RZLT vs. GLUE, SLS, CAPR, IMCR, and VIR

How does Rezolute compare to Monte Rosa Therapeutics?

Do analysts rate GLUE or RZLT?

Do insiders and institutionals have more ownership in GLUE or RZLT?

Is GLUE or RZLT more profitable?

Does the media prefer GLUE or RZLT?

Which has higher earnings & valuation, GLUE or RZLT?

Which has more volatility and risk, GLUE or RZLT?

Summary

How does Rezolute compare to SELLAS Life Sciences Group?

Which has more risk and volatility, SLS or RZLT?

Which has stronger valuation and earnings, SLS or RZLT?

Do institutionals & insiders have more ownership in SLS or RZLT?

Is SLS or RZLT more profitable?

Do analysts recommend SLS or RZLT?

Does the media favor SLS or RZLT?

Summary

How does Rezolute compare to Capricor Therapeutics?

Do insiders & institutionals have more ownership in CAPR or RZLT?

Which has more volatility and risk, CAPR or RZLT?

Is CAPR or RZLT more profitable?

Does the media favor CAPR or RZLT?

Which has better earnings & valuation, CAPR or RZLT?

Do analysts prefer CAPR or RZLT?

Summary

How does Rezolute compare to Immunocore?

Do analysts prefer RZLT or IMCR?

Which has more risk & volatility, RZLT or IMCR?

Which has higher valuation and earnings, RZLT or IMCR?

Is RZLT or IMCR more profitable?

Do institutionals and insiders believe in RZLT or IMCR?

Does the media favor RZLT or IMCR?

Summary

How does Rezolute compare to Vir Biotechnology?

Which has higher valuation and earnings, RZLT or VIR?

Do analysts prefer RZLT or VIR?

Which has more risk & volatility, RZLT or VIR?

Do institutionals and insiders believe in RZLT or VIR?

Is RZLT or VIR more profitable?

Does the media favor RZLT or VIR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RZLT vs. The Competition

Rezolute Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools